About Us

Rasna Therapeutics was formed in 2013 by a highly experienced industry team together with field-leading scientists, to focus on developing therapeutics to address the high unmet need that exists for AML and other forms of leukemia.

Our primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients.

Our clinical program is based around two druggable intervention points with potential to improve safety and efficacy of current AML combination therapies.

OTCQB:RASP

Rasna is listed as OTCQB:RASP.

Our corporate headquarters are based in New York, NY, while our research and development team is located at our laboratory facilities in Doylestown Pennsylvania.

2013

Founded

2016

Quoted OTCQB:RASP

AML

Focused on Acute Myeloid Leukemia and other blood cancers

Lead programmes in the clinic, each targeting a key regulator of cancer

Therapeutic Focus

What is Leukemia?

“Leukemia” is the name given to a broad group of cancers where blood cells proliferate abnormally
Leukemia is the fifth most common cause of cancer death in men and sixth most common cause of cancer death in women.
According to the Leukemia & Lymphoma Society, in the United States, around 62,000 new diagnoses and 24,500 deaths are expected in 2017 from Leukemia.
Leukemia is caused by mutation of DNA in bone marrow stem cells which results in the abnormal proliferation of white blood cells (leukocytes). Mutations may occur spontaneously, or as a result of exposure to ionizing radiation or carcinogens.
Leukemia is deadly because as the disease progresses, leukemic cells ultimately overwhelm the bone marrow, enter the bloodstream and become invasive to other parts of the body, such as the lymph nodes, spleen, liver, and central nervous system.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML), our primary indication, is the most common type of acute leukemia in adults and progresses rapidly.
Estimated new cases and deaths from AML in the United States in 2017

New Cases: 21,380
Deaths: 10,590
A sub-type of leukemia where the bone marrow starts to make abnormal myeloblasts, red blood cells or platelets.
Untreated, may be fatal within weeks to months, with a 5-year survival rate of ~25% and long term survival in aged patients of almost zero.
Despite advances in treatment, there is currently a high risk of relapse and serious side effects from each treatment round

Source: American Cancer Society: Cancer Facts and Figures 2017.

LEUKEMIA SUB-TYPES

MYELOGENOUS	LYMPHOCYTIC
Acute Myeloid AML is most common in adults, especially men Makes up 28% cases Lowest five-year survival rate of the four main leukemia sub-types, at only 26%	Acute Lymphocytic ALL is more common among children Makes up 13% cases Five-year survival rate of 70%	44% of cases
Chronic Myeloid CML occurs predominantly in adults and is rare in children Makes up 13% cases Five-year survival rate of 63%	Chronic Lymphocytic CLL is most common in adults especially men above 55 years of age Makes up 30% cases Five-year survival rate of ~85%	43% of cases

MYELOGENOUS

LYMPHOCYTIC

Acute Myeloid

AML is most common in adults, especially men
Makes up 28% cases
Lowest five-year survival rate of the four main leukemia sub-types, at only 26%

Acute Lymphocytic

ALL is more common among children
Makes up 13% cases
Five-year survival rate of 70%

44% of cases

Chronic Myeloid

CML occurs predominantly in adults and is rare in children
Makes up 13% cases
Five-year survival rate of 63%

Chronic Lymphocytic

CLL is most common in adults especially men above 55 years of age
Makes up 30% cases
Five-year survival rate of ~85%

43% of cases

Our Team

Scientific Advisors

Brunangelo Falini MD

University of Perugia

Roberto Pellicciari PhD

University of Perugia

Board

Willy Simon

Chairman

John Brancaccio

Director

Gary S. Jacob

Director

R&D Pipeline

RASP-201

LSD1
LYSINE-SPECIFIC
DEMETHYLASE 1

Novel inhibitors of LSD-1, a pathway that blocks differentiation and confers a poor prognosis in AML. LSD-1 has already been identified as a important druggable target

Learn more

RASP-301

NPM1
NUCLEOPHOSMIN

A first in class NCE for NPM1, currently at the pre-clinical stage, this orally available small molecule has the potential to treat refractory AML with reduced toxicity.

Learn more

Contact Us

US HEAD OFFICE

420 Lexington Avenue, Suite 2525
New York, NY 10170
USA

info@rasna.com \\ Tel: [+1] (646) 396-4080

UK HEAD OFFICE

55 Park Lane
London W1K 1NA
United Kingdom

info@rasna.com \\ Tel: [+44] (0) 207 495 2379

R&D Center

Pennsylvania Biotechnology Center of Bucks County
3805 Old Easton RD
Doylestown, PA 18902-8400
USA

info@rasna.com \\ Tel: [+1] (215) 589-6300